The proposed pilot study will compare minocycline augmentation with clozapine in individuals
with high vs low inflammation as measured by CRP. Investigators hypothesize that minocycline
will be well tolerated and will result in an improvement in the symptoms of schizophrenia,
cognition, as well as improve the quality of life for patients preferentially in patients
with high CRPs. Investigators plan to use a variety of different scales to measure
improvement in the varying symptoms of schizophrenia as well as cognitive function, which
will be administered to patients at three week intervals for a total study time of twelve
weeks. Investigators hypothesize that minocycline could prove to be an effective, well
tolerated, and inexpensive medication for treatment resistant patients with schizophrenia
whom have particular difficulties with social interactions, obtaining and maintaining
employment, and overall quality of life. Furthermore, investigators hypothesize that the data
obtained in this study will contribute to the ongoing exploration of the role of inflammation
in the brain of patients with schizophrenia and help understand and target the role of
various inflammatory markers in the pathophysiology and treatment of treatment resistant
schizophrenia.